Neuropeptide Y accounts for sympathetic vasoconstriction in guinea-pig vena cava: evidence using BIBP 3226 and 3435

Abstract

The ability of the novel, non-peptide, neuropeptide Y Y 1 receptor antagonist, BIBP 3226 (( R)- N 2-(diphenylacetyl)- N-[(4-hydroxyphenyl)methyl]-argininamide), to antagonize neuropeptide Y- and sympathetic-mediated vasoconstriction was examined in isolated segments of the thoracic vena cava of guinea-pigs. Increasing concentrations (10 −9–10 −6 M) of BIBP 3226 caused a parallel and rightward shift in the neuropeptide Y dose-response curve but did not significantly change the effect of noradrenaline. The calculated pA 2 value for BIBP 3226 was 8.0 ± 0.08, a value fully compatible with the reported affinity at rodent and human neuronal Y 1 receptors. BIBP 3226 (10 −6 M) also readily reversed the established vasocontraction induced by neuropeptide Y. BIBP 3226 (10 −6 M) markedly inhibited the slow long-lasting contraction evoked by high frequency electrical field stimulation, leaving a rapid component which was abolished by phentolamine. Its enantiomer, BIBP 3435 (( S)- N 2-(diphenylacetyl)- N-[(4-hydroxyphenyl)methyl]-argininamide), which exerts a much weaker action on neuropeptide Y Y 1 receptors, had no such inhibitory effect. In propranolol-pretreated vessels, the vasoconstriction evoked by nerve stimulation was enhanced; then BIBP 3226 inhibited the peak response by 44%, and the integrated contractile effect by 90%. We conclude that BIBP 3226 is a potent and competitive antagonist of neuropeptide Y Y 1 receptor-mediated vasoconstriction in guinea-pig vena cava and that endogenous neuropeptide Y acting on the neuropeptide Y Y 1 receptor is likely to account for the long-lasting component of the sympathetic vasoconstriction in response to high-frequency stimulation in this vessel.